About: DPP-4 Inhibitors in the Prevention/Treatment of Pulmonary Fibrosis, Heart and Kidney Injury Caused by COVID-19—A Therapeutic Approach of Choice in Type 2 Diabetic Patients?

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: DPP-4 Inhibitors in the Prevention/Treatment of Pulmonary Fibrosis, Heart and Kidney Injury Caused by COVID-19—A Therapeutic Approach of Choice in Type 2 Diabetic Patients? Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	DPP-4 Inhibitors in the Prevention/Treatment of Pulmonary Fibrosis, Heart and Kidney Injury Caused by COVID-19—A Therapeutic Approach of Choice in Type 2 Diabetic Patients?
Creator	Anderluh, Marko Djordjevic, Vukica Gajic, Mihajlo Kocic, Gordana Smelcerovic, Andrija Stankovic-Djordjevic, Dobrila Tomovic, Katarina
Source	Medline; PMC
abstract	Since the outbreak of SARS-CoV-2 virus more than 12,500,000 cases have been reported worldwide. Patients suffering from diabetes and other comorbidities are particularly susceptible to severe forms of the COVID-19, which might result in chronic complications following recovery. Dipeptidyl peptidase-4 inhibitors exert beneficial effects in prevention/treatment of pulmonary fibrosis, heart, and kidney injury, and since they may be a long-term consequence caused by COVID-19, it is reasonable to expect that DPP-4 inhibitors might be beneficial in alleviating long-term consequences of COVID-19. With that in mind, we would like to voice our concerns over chronic implications following recovery from COVID-19, especially not only in diabetic but also in non-diabetic patients, and to indicate that some preventive measures could be undertaken by application of DPP-4 inhibitors.
has issue date	2020-08-05(xsd:dateTime)
bibo:doi	10.3389/fphar.2020.01185
bibo:pmid	32848788
has license	cc-by
sha1sum (hex)	9d77ecc96077be105bde9ba70d6968b629d5fc9f
schema:url	https://doi.org/10.3389/fphar.2020.01185
resource representing a document's title	DPP-4 Inhibitors in the Prevention/Treatment of Pulmonary Fibrosis, Heart and Kidney Injury Caused by COVID-19—A Therapeutic Approach of Choice in Type 2 Diabetic Patients?
has PubMed Central identifier	PMC7419672
has PubMed identifier	32848788
schema:publication	Front Pharmacol
resource representing a document's body	covid:9d77ecc96077be105bde9ba70d6968b629d5fc9f#body_text
is schema:about of	named entity 'DPP-4 Inhibitors' named entity 'Pulmonary Fibrosis' named entity 'pulmonary fibrosis' named entity 'preventive measures' named entity 'SARS-CoV-2' named entity 'DPP-4 inhibitors' named entity 'DPP-4 inhibitors' named entity 'hypertension' named entity 'critically ill patients' named entity 'long-term' named entity 'myofibroblasts' named entity 'DPP-4 inhibitors' named entity 'comorbidities' named entity 'ACE2' named entity 'kidney function' named entity 'case fatality' named entity 'long-term' named entity 'Pozzilli' named entity 'diabetic patients' named entity 'diabetes' named entity 'stromal cell-derived factor-1' named entity 'anti-inflammatory' named entity 'COVID' named entity 'anti-inflammatory' named entity 'Serbian Academy of Sciences and Arts' named entity 'diabetes mellitus type 2' named entity 'glycemic control' named entity 'antiinflammatory' named entity 'lungs' named entity 'pulmonary injury' named entity 'long-term' named entity 'complex diseases' named entity 'comorbidities' named entity 'fibrotic' named entity 'type 2 diabetes mellitus' named entity 'pulmonary function' named entity 'Coronavirus' named entity 'COVID' named entity 'pleiotropic' named entity 'lung' named entity 'Epidemiology' named entity 'infection' named entity 'non-diabetic' named entity 'SARS-CoV-2' named entity 'fibroblasts' named entity 'diabetes' named entity 'fibrosis' named entity 'kidney injury' named entity 'Pneumonia' named entity 'DPP-4 inhibitors' named entity 'DPP-4 inhibition' named entity 'coronavirus infections' named entity 'infection' named entity 'DPP-4 inhibition' named entity 'anti-fibrotic' named entity 'Coronavirus' named entity 'type 2 diabetes mellitus' named entity 'lungs' named entity 'anti-fibrotic' named entity 'diabetes' named entity 'DPP-4 inhibitors' named entity 'University of Nis' named entity 'pathology' named entity 'COVID' named entity 'vaccines' named entity 'COVID' named entity 'anti-proliferative' named entity 'risk factor' named entity 'hypertension' named entity 'Frontiers in Pharmacology' named entity 'COVID' named entity 'public health' named entity 'COVID' named entity 'Pneumonia' named entity 'corticosteroids'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software